12 Month Price Forecast For HAE
Distance to HAE Price Forecasts
HAE Price Momentum
๐ค Considering Haemonetics (HAE)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 3:24 AM UTC
HAE Analyst Ratings & Price Targets
Based on our analysis of 14 Wall Street analysts, HAE has a bullish consensus with a median price target of $97.50 (ranging from $68.00 to $120.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $62.36, the median forecast implies a 56.4% upside. This outlook is supported by 8 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Andrew Cooper at Raymond James, projecting a 92.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HAE Analyst Consensus
HAE Price Target Range
Latest HAE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HAE.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 7, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $95.00 |
Feb 7, 2025 | Needham | Mike Matson | Buy | Maintains | $108.00 |
Feb 7, 2025 | JMP Securities | David Turkaly | Market Outperform | Maintains | $100.00 |
Feb 7, 2025 | Raymond James | Andrew Cooper | Strong Buy | Reiterates | $115.00 |
Dec 6, 2024 | JP Morgan | Rohin Patel | Overweight | Initiates | $116.00 |
Dec 4, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $108.00 |
Dec 3, 2024 | Needham | Mike Matson | Buy | Reiterates | $112.00 |
Nov 15, 2024 | Needham | Mike Matson | Buy | Reiterates | $112.00 |
Nov 8, 2024 | Raymond James | Andrew Cooper | Strong Buy | Upgrade | $120.00 |
Nov 8, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $108.00 |
Sep 23, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $108.00 |
Sep 13, 2024 | CL King | Kristen Stewart | Buy | Initiates | $116.00 |
Sep 11, 2024 | B of A Securities | Craig Bijou | Neutral | Initiates | $85.00 |
Sep 10, 2024 | BTIG | Marie Thibault | Buy | Initiates | $112.00 |
Aug 22, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $85.00 |
Aug 13, 2024 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $125.00 |
Aug 9, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $108.00 |
Jun 12, 2024 | Needham | Mike Matson | Buy | Upgrade | $112.00 |
May 10, 2024 | JMP Securities | David Turkaly | Market Outperform | Maintains | $125.00 |
May 10, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $107.00 |
Stocks Similar to Haemonetics Corp
The following stocks are similar to Haemonetics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Haemonetics Corp (HAE) Financial Data
Haemonetics Corp has a market capitalization of $3.14B with a P/E ratio of 24.6x. The company generates $1.36B in trailing twelve-month revenue with a 9.1% profit margin.
Revenue growth is +8.6% quarter-over-quarter, while maintaining an operating margin of +16.4% and return on equity of +14.0%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Haemonetics Corp (HAE) Company Overview
About Haemonetics Corp
Provides medical products and solutions for blood management.
The company generates revenue by selling a range of medical products, including automated plasma collection systems, blood component collection systems, and donor management software. Its business model relies on direct sales, independent distributors, and sales representatives to reach various healthcare providers and organizations, ensuring efficient blood and plasma management.
Founded in 1971 and headquartered in Boston, Massachusetts, the company focuses on innovative technologies that enhance donor and patient care. Its products are essential for hospitals and blood banks, positioning the company as a key player in the healthcare sector, particularly in blood management and transfusion solutions.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
3,657
CEO
Mr. Christopher A. Simon
Country
United States
IPO Year
1991
Website
www.haemonetics.comHaemonetics Corp (HAE) Latest News & Analysis
Haemonetics Corporation (NYSE:HAE) will hold its Q3 2025 Earnings Conference Call on February 6, 2025, at 8:30 AM ET, featuring key executives and financial analysts.
The earnings conference call provides insights into Haemonetics' financial performance and strategic direction, which can influence stock valuation and investor sentiment.
Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website
9 days agoHaemonetics Corporation (NYSE: HAE) released its Q3 fiscal year 2025 financial results, ending December 28, 2024. A conference call will be held at 8:00 a.m. for discussion and Q&A.
Haemonetics' Q3 fiscal results and upcoming conference call may impact stock performance, providing insights into financial health and guidance for future growth.
Haemonetics (HAE) Q3 Earnings Meet Estimates
9 days agoHaemonetics (HAE) reported Q2 earnings of $1.19 per share, matching the Zacks Consensus Estimate and up from $1.04 per share year-over-year.
Haemonetics' earnings match expectations and show year-over-year growth, indicating stability and potential for future profitability, which can influence investor confidence and stock performance.
Haemonetics (HAE) reported its revenue and EPS for Q4 2024, highlighting performance against Wall Street estimates and year-ago figures.
Comparing Haemonetics' revenue and EPS to Wall Street estimates and year-ago figures indicates market performance, potential growth, and investment viability.
Haemonetics reported strong third-quarter fiscal 2025 results, showing significant earnings growth and margin expansion, attributed to its long-range strategic plan.
Haemonetics' strong earnings growth and margin expansion signal effective long-term strategies, potentially boosting investor confidence and driving stock performance.
Zacks Style Scores can help investors identify strong, market-beating stocks for their portfolios.
The Zacks Style Scores can guide investors in identifying high-potential stocks, enhancing portfolio performance and potentially leading to better returns.
Frequently Asked Questions About HAE Stock
What is Haemonetics Corp's (HAE) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Haemonetics Corp (HAE) has a median price target of $97.50. The highest price target is $120.00 and the lowest is $68.00.
Is HAE stock a good investment in 2025?
According to current analyst ratings, HAE has 8 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $62.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for HAE stock?
Wall Street analysts predict HAE stock could reach $97.50 in the next 12 months. This represents a 56.4% increase from the current price of $62.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Haemonetics Corp's business model?
The company generates revenue by selling a range of medical products, including automated plasma collection systems, blood component collection systems, and donor management software. Its business model relies on direct sales, independent distributors, and sales representatives to reach various healthcare providers and organizations, ensuring efficient blood and plasma management.
What is the highest forecasted price for HAE Haemonetics Corp?
The highest price target for HAE is $120.00 from Andrew Cooper at Raymond James, which represents a 92.4% increase from the current price of $62.36.
What is the lowest forecasted price for HAE Haemonetics Corp?
The lowest price target for HAE is $68.00 from at , which represents a 9.0% increase from the current price of $62.36.
What is the overall HAE consensus from analysts for Haemonetics Corp?
The overall analyst consensus for HAE is bullish. Out of 14 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $97.50.
How accurate are HAE stock price projections?
Stock price projections, including those for Haemonetics Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.